Volume : 09, Issue : 12, December – 2022
Title:
05.OVERVIEW OF CAFFEINE CITRATE ROLES IN NEONATAL APNEA
Authors :
Amaal basrwan*,-Raghdah Nuri shaban, -Dhaifallah abdulaziz alzahrani, -Hussein Abdul Mohsen Al-Maqati, Khaled Ali babalghith, -Ehab ayman soqaty, -Ahmed Hassan Alhadri, -Nany Mohammed Nawwar, -Ebtissam Mohammad Badawoud, -Abdullah Ibrahim Zakri,
Abstract :
Caffeine is the most commonly administered drug in neonatal critical care units. It is used for the prevention and treatment of apnea, despite being linked to a decreased risk of bronchopulmonary dysplasia (BPD) in infants aged 18 to 21 months. We conducted a comprehensive search of EMBASE, the Cochrane Database of Systematic Reviews (CDSR), and PubMed from inception to January 2022 using variations of the key phrases “apnea,” “caffeine,” “intensive care, neonatal,” and “baby, newborn” to discover relevant literature. However, its influence on BPD and neurodevelopmental outcomes may be mediated by its anti-inflammatory mediator, white matter protection, and induction of surfactant protein B effects. Despite the fact that long-term studies have demonstrated the safety of caffeine as it is currently administered, it is evident that additional research is required to determine the optimal dosage, as well as the timing of initiation and cessation.
Cite This Article:
Please cite this article in press Amaal basrwan et al, Overview Of Caffeine Citrate Roles In Neonatal Apnea.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
1. Finer NN, Barrington KJ, Hayes BJ, Hugh A. Obstructive, mixed, and central apnea in the neonate: physiologic correlates. J Pediatr. 1992;121(6):943–950.
2. Kondamudi NP, Wilt AS. Infant apnea. Florida: StatPearls Publishing; 2020. [
3. Aujard Y. Caffeine in the treatment of apnea in premature infants. Arch Fr Pediatr. 1990;47(10):763.
4. Kreutzer K, Bassler D. Caffeine for apnea of prematurity: a neonatal success story. Neonatology. 2014;105(4):332–336.
5. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–2121.
6. Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, Dewey D, D’Ilario J, Doyle LW, Grunau RE. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial. JAMA Pediatr. 2017;171(6):564–572.
7. Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr. (2011) 170:1097–105. 10.1007/s00431-011-1409-6.
8. Theobald K, Botwinski C, Albanna S, McWilliam P. Apnea of prematurity: diagnosis, implications for care, and pharmacologic management. Neonatal Netw. (2000) 19:17–24.
9. Poets CF, Roberts RS, Schmidt B, Whyte RK, Asztalos EV, Bader D, et al. Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. JAMA. (2015) 314:595–603.
10. Eichenwald EC, American Academy of Pediatrics Committee on Fetus and Newborn . Apnea of prematurity. Pediatrics. (2016) 137:e20153757.
11. Sims ME, Yau G, Rambhatla S, Cabal L, Wu PY. Limitations of theophylline in the treatment of apnea of prematurity. Am J Dis Child. (1985) 139:567–70. 10.1001/archpedi.1985.02140080037028.
12. Murat I, Moriette G, Blin MC, Couchard M, Flouvat B, De Gamarra E, et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr. (1981) 99:984–9.
13. Chen J, Jin L, Chen X. Efficacy and safety of different maintenance doses of caffeine citrate for treatment of apnea in premature infants: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:9061234.
14. Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010(1).
15. Henderson-Smart DJ, Steer PA. Doxapram versus methylxanthine for apnea in preterm infants. Cochrane Database of Systematic Reviews 2000(4).
16. Henderson-Smart DJ, De Paoli AG: Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst. Rev. 2010(12).
17. Vliegenthart R, Miedema M, Hutten GJ, van Kaam AH, Onland W. High versus standard dose caffeine for apnoea: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2018;103(6):F523–F529.
18. Brattström P, Russo C, Ley D, Bruschettini M. High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis. Acta Paediatr. 2019;108(3):401–410.
19. Natarajan G, Botica M-L, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics 2007;119:936e40.
20. Boutroy MJ, Vert P, Royer RJ, Monin P, Royer-Morrot MJ. Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant. J Pediatr 1979;94:996e8.
21. Atik A, Harding R, De Matteo R, et al. Caffeine for apnea of prematurity: effects on the developing brain. Neurotoxicology 2017;58:94e102.
22. Julien CA, Joseph V, Bairam A. Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. Pediatr Res 2010;68:105e11.
23. Herlenius E, Lagercrantz H, Yamamoto Y. Adenosine modulates inspiratory neurons and the respiratory pattern in the brainstem of neonatal rats. Pediatr Res 1997;42:46e53.
24. Blanchard PW, Cot ^ e A, Hobbs S, Foulon P, Aranda JV, Bureau MA. Abolition of ventilatory response to caffeine in chemodenervated lambs. J Appl Physiol 1986;61:133e7.
25. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;311:349e53.
26. Maycock DE, Standaert TA, Watchko JF, Woodrum DE. Effect of aminophylline on diaphragmatic contractility in the piglet. Pediatr Res 1990;28:196e8.
27. Parikka V, Beck J, Zhai Q, Leppasalo J, Lehtonen L, Soukka H. The effect of € caffeine citrate on neural breathing pattern in preterm infants. Early Hum Dev 2015;91:565e8.
28. Davis JM, Bhutani VK, Stefano JL, Fox WW, Spitzer AR. Changes in pulmonary mechanics following caffeine administration in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989;6:49e52.
29. Back SA, Craig A, Luo NL, et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 2006;60: 696e705.
30. Rivkees SA, Wendler CC. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr Res 2011;69:271e8.
31. Murat I, Moriette G, Blin MC, Couchard M, Flouvat B, De Gamarra E, et al.. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr. (1981) 99:984–9. 10.1016/S0022-3476(81)80038-
32. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy. (2000) 20:644–52.
33. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al.. Caffeine therapy for apnea of prematurity. N Engl J Med. (2006) 354:2112–21. 10.1056/NEJMoa054065.
34. Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, et al.. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity. JAMA Pediatr. (2017) 171:564.
35. Chiesi Limited Peyona (Caffeine Citrate) 20 mg/ml Solution for Infusion and Oral Solution: Summary of Product Characteristics. (2017). Available online at: https://www.medicines.org.uk/emc/medicine/26467.
36. Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. (2001) 107:660–3. 10.1542/peds.107.4.660
37. Carnielli VP, Verlato G, Benini F, et al. Metabolic and respiratory effects of theophylline in the preterm infant. Archs Dis Childh Fetal Neonatal Ed 2000;83:F39e43.
38. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112e21.
2. Kondamudi NP, Wilt AS. Infant apnea. Florida: StatPearls Publishing; 2020. [
3. Aujard Y. Caffeine in the treatment of apnea in premature infants. Arch Fr Pediatr. 1990;47(10):763.
4. Kreutzer K, Bassler D. Caffeine for apnea of prematurity: a neonatal success story. Neonatology. 2014;105(4):332–336.
5. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–2121.
6. Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, Dewey D, D’Ilario J, Doyle LW, Grunau RE. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial. JAMA Pediatr. 2017;171(6):564–572.
7. Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr. (2011) 170:1097–105. 10.1007/s00431-011-1409-6.
8. Theobald K, Botwinski C, Albanna S, McWilliam P. Apnea of prematurity: diagnosis, implications for care, and pharmacologic management. Neonatal Netw. (2000) 19:17–24.
9. Poets CF, Roberts RS, Schmidt B, Whyte RK, Asztalos EV, Bader D, et al. Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. JAMA. (2015) 314:595–603.
10. Eichenwald EC, American Academy of Pediatrics Committee on Fetus and Newborn . Apnea of prematurity. Pediatrics. (2016) 137:e20153757.
11. Sims ME, Yau G, Rambhatla S, Cabal L, Wu PY. Limitations of theophylline in the treatment of apnea of prematurity. Am J Dis Child. (1985) 139:567–70. 10.1001/archpedi.1985.02140080037028.
12. Murat I, Moriette G, Blin MC, Couchard M, Flouvat B, De Gamarra E, et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr. (1981) 99:984–9.
13. Chen J, Jin L, Chen X. Efficacy and safety of different maintenance doses of caffeine citrate for treatment of apnea in premature infants: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:9061234.
14. Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010(1).
15. Henderson-Smart DJ, Steer PA. Doxapram versus methylxanthine for apnea in preterm infants. Cochrane Database of Systematic Reviews 2000(4).
16. Henderson-Smart DJ, De Paoli AG: Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst. Rev. 2010(12).
17. Vliegenthart R, Miedema M, Hutten GJ, van Kaam AH, Onland W. High versus standard dose caffeine for apnoea: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2018;103(6):F523–F529.
18. Brattström P, Russo C, Ley D, Bruschettini M. High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis. Acta Paediatr. 2019;108(3):401–410.
19. Natarajan G, Botica M-L, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics 2007;119:936e40.
20. Boutroy MJ, Vert P, Royer RJ, Monin P, Royer-Morrot MJ. Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant. J Pediatr 1979;94:996e8.
21. Atik A, Harding R, De Matteo R, et al. Caffeine for apnea of prematurity: effects on the developing brain. Neurotoxicology 2017;58:94e102.
22. Julien CA, Joseph V, Bairam A. Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. Pediatr Res 2010;68:105e11.
23. Herlenius E, Lagercrantz H, Yamamoto Y. Adenosine modulates inspiratory neurons and the respiratory pattern in the brainstem of neonatal rats. Pediatr Res 1997;42:46e53.
24. Blanchard PW, Cot ^ e A, Hobbs S, Foulon P, Aranda JV, Bureau MA. Abolition of ventilatory response to caffeine in chemodenervated lambs. J Appl Physiol 1986;61:133e7.
25. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;311:349e53.
26. Maycock DE, Standaert TA, Watchko JF, Woodrum DE. Effect of aminophylline on diaphragmatic contractility in the piglet. Pediatr Res 1990;28:196e8.
27. Parikka V, Beck J, Zhai Q, Leppasalo J, Lehtonen L, Soukka H. The effect of € caffeine citrate on neural breathing pattern in preterm infants. Early Hum Dev 2015;91:565e8.
28. Davis JM, Bhutani VK, Stefano JL, Fox WW, Spitzer AR. Changes in pulmonary mechanics following caffeine administration in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989;6:49e52.
29. Back SA, Craig A, Luo NL, et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 2006;60: 696e705.
30. Rivkees SA, Wendler CC. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr Res 2011;69:271e8.
31. Murat I, Moriette G, Blin MC, Couchard M, Flouvat B, De Gamarra E, et al.. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr. (1981) 99:984–9. 10.1016/S0022-3476(81)80038-
32. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy. (2000) 20:644–52.
33. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al.. Caffeine therapy for apnea of prematurity. N Engl J Med. (2006) 354:2112–21. 10.1056/NEJMoa054065.
34. Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, et al.. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity. JAMA Pediatr. (2017) 171:564.
35. Chiesi Limited Peyona (Caffeine Citrate) 20 mg/ml Solution for Infusion and Oral Solution: Summary of Product Characteristics. (2017). Available online at: https://www.medicines.org.uk/emc/medicine/26467.
36. Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. (2001) 107:660–3. 10.1542/peds.107.4.660
37. Carnielli VP, Verlato G, Benini F, et al. Metabolic and respiratory effects of theophylline in the preterm infant. Archs Dis Childh Fetal Neonatal Ed 2000;83:F39e43.
38. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112e21.